RT Journal Article
SR Electronic
T1 Natalizumab (Tysabri)
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 1588
OP 1590
DO 10.3174/ajnr.A2226
VO 31
IS 9
A1 Selewski, D.T.
A1 Shah, G.V.
A1 Segal, B.M.
A1 Rajdev, P.A.
A1 Mukherji, S.K.
YR 2010
UL http://www.ajnr.org/content/31/9/1588.abstract
AB SUMMARY: Natalizumab is a humanized IgG4κ monoclonal antibody that is a selective adhesion molecule inhibitor, which prevents adhesion of leukocytes to endothelial cells. It is the first monoclonal antibody approved by the FDA for the treatment of relapsing-remitting MS. This article will review the mechanism of action and clinical role of this agent. FDAUS Food and Drug AdministrationFLAIRfluid-attenuated inversion recoveryFSEfast spin-echoIgGimmunoglobulin GMAdCAM-1mucosal adressin cell adhesion moleculeMSmultiple sclerosisPMLprogressive multifocal leukoencephalopathyTOUCHTysabri Outreach Unified Commitment to HealthVCAM -1vascular cell adhesion molecule-1